Skip to main content

Table 1 Patient characteristics according to tumor subtype

From: Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

 

HR + /HER2 − 

(N = 13,283)

TN

(N = 2845)

HR + /HER2 + 

(N = 2502)

HR − /HER2 + 

(N = 1403)

Total

(N = 20,033)

Age (years) (median, [IQR])

62.0 (51.0, 71.0)

56.0 (45.0, 66.0)

57.0 (47.0, 67.0)

56.0 (46.5, 64.0)

60.0 (50.0, 70.0)

Personal history of other cancer

401 (3.0%)

111 (3.9%)

75 (3.0%)

38 (2.7%)

625 (3.1%)

Histologic type (primary tumor)

 IDC

9498 (71.5%)

2382 (83.7%)

2045 (81.7%)

1185 (84.5%)

15,110 (75.4%)

 ILC

2263 (17.0%)

123 (4.3%)

168 (6.7%)

44 (3.1%)

2598 (13.0%)

 IDC + ILC

149 (1.1%)

8 (0.3%)

28 (1.1%)

4 (0.3%)

189 (0.9%)

 Other types

1173 (8.8%)

296 (10.4%)

227 (9.1%)

155 (11.0%)

1851 (9.2%)

 Not documented

200 (1.5%)

36 (1.3%)

34 (1.4%)

15 (1.1%)

285 (1.4%)

Histological grade (primary tumor)

 Grade 1

1532 (11.5%)

46 (1.6%)

132 (5.3%)

16 (1.1%)

1726 (8.6%)

 Grade 2

6883 (51.8%)

758 (26.6%)

1125 (45.0%)

459 (32.7%)

9225 (46.0%)

 Grade 3

2775 (20.9%)

1662 (58.4%)

866 (34.6%)

724 (51.6%)

6027 (30.1%)

 Not documented

2093 (15.8%)

379 (13.3%)

379 (15.1%)

204 (14.5%)

3055 (15.2%)

De novo mBC disease

 Yes

4217 (31.7%)

872 (30.7%)

1017 (40.6%)

687 (49.0%)

6793 (33.9%)

 No

9066 (68.3%)

1973 (69.3%)

1485 (59.4%)

716 (51.0%)

13,240 (66.1%)

For patients without de novo mBC disease: metastasis free interval [MFI]

 − [6:24[

1109 (8.3%)

1043 (36.7%)

235 (9.4%)

280 (20.0%)

2667 (13.3%)

 − [24:48[

1939 (14.6%)

484 (17.0%)

449 (17.9%)

238 (17.0%)

3110 (15.5%)

 − [48:96[

2528 (19.0%)

224 (7.9%)

423 (16.9%)

121 (8.6%)

3296 (16.5%)

 − [96:120[

955 (7.2%)

42 (1.5%)

112 (4.5%)

29 (2.1%)

1138 (5.7%)

 −  >  = 120

2535 (19.1%)

180 (6.3%)

266 (10.6%)

48 (3.4%)

3029 (15.1%)

For patients without de novo mBC disease, therapy used in adjuvant setting (*)

 IV chemotherapy

6094 (67.2%)

1752 (88.8%)

1136 (76.5%)

601 (83.9%)

9583 (72.4%)

 Oral chemotherapy

149 (1.6%)

80 (4.1%)

52 (3.5%)

27 (3.8%)

308 (2.3%)

 Endocrine therapy

7582 (83.6%)

76 (3.9%)

1175 (79.1%)

30 (4.2%)

8863 (66.9%)

Number of metastatic sites at mBC diagnosis

 < 3

10,627 (80.0%)

2135 (75.0%)

1984 (79.3%)

1077 (76.8%)

15,823 (79.0%)

 >  = 3

2656 (20.0%)

710 (25.0%)

518 (20.7%)

326 (23.2%)

4210 (21.0%)

 Brain/CNS/CSF metastases

543 (4.1%)

359 (12.6%)

227 (9.1%)

201 (14.3%)

1330 (6.6%)

 Bone metastases

8678 (65.3%)

1007 (35.4%)

1375 (55.0%)

541 (38.6%)

11,601 (57.9%)

 Liver metastases

3378 (25.4%)

787 (27.7%)

802 (32.1%)

546 (38.9%)

5513 (27.5%)

 Lung metastases

2783 (21.0%)

1024 (36.0%)

639 (25.5%)

420 (29.9%)

4866 (24.3%)

 Metastatic lymph nodes

3458 (26.0%)

1235 (43.4%)

751 (30.0%)

506 (36.1%)

5950 (29.7%)

 Pleural metastases

1444 (10.9%)

296 (10.4%)

178 (7.1%)

108 (7.7%)

2026 (10.1%)

  1. (*) Percentages may not sum up to 100% as patients may receive more than one adjuvant treatment
  2. Abbreviations: IQR, interquartile range; BC, breast cancer; mBC, metastatic breast cancer; HR + , presence of hormone receptor; HR − , absence of hormone receptor; HER2 + , human epidermal growth factor receptor 2 (HER2) protein overexpression; HER2 − , no HER2 protein overexpression; TN, triple negative; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IV, intravenous; PO, per os; CNS, central nervous system; CSF, cerebrospinal fluid